Uncategorised - European Medical Journal

Twenty-five years of etanercept

Rheumatologist Rieke Alten discusses how treat-to-target care and TNF inhibition with etanercept reshape RA outcomes, with safety…

Long-Acting Therapeutics for HIV

Key takeaways from the symposia. Impact of LA options on the future of treatment and prevention. Opportunities and challenges for…

4 Dec 2025

Evidence on VNS in the Modern DRE Treatment Landscape

In this interactive article, explore how drug-resistant epilepsy is linked to decreased quality of life and increased risk of morbidity and..

Clinical trial participant

ABPI: UK falling behind on clinical trial recruitment

According to the body, patient participation in industry-sponsored trials has fallen by 25% between 2022/23 and 2024/25.

Older man using user-centred digital solutions for non-melanoma skin cancer care on a phone at home

Designing User-Centred Digital Solutions In Skin Cancer Care

User-centered digital solutions may ease care pathways for plastic surgery patients with non-melanoma skin cancer.

Generational Gaps in Vaccine Acceptance in the US

This study reveals how age and partisanship shape COVID-19 vaccine acceptance in the USA during rollout.

Aluminum Adjuvant Imject Alum Drives Liver Fibrosis in Novel Mouse Model

High-dose aluminum adjuvant Imject Alum induces immune-mediated liver inflammation and fibrosis in mice, offering a new preclinical model that mirrors human cirrhosis biology.

Intradermal botulinum toxin A injection concept for post acne erythema on the face

Treating Post Acne Redness with Botulinum Toxin A

Intradermal botulinum toxin A for post acne erythema outperformed broadband light in this split face randomized controlled trial.

New Guideline Enhances Safe csDMARD Use Nationwide

BSR has published an updated guideline on the safe use of csDMARDs, introducing new evidence, paediatric guidance, and risk-adaptive monitoring across the full life course.

glioblastoma

Engineered Virus Shows New Hope Against Deadly Brain Cancer

Engineered herpes virus targets glioblastoma cells, destroying tumours while activating immune defences in preclinical brain cancer models.